Literature DB >> 15253107

Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney.

Kazunori Sato1, Akira Sugawara, Masataka Kudo, Akira Uruno, Sadayoshi Ito, Kazuhisa Takeuchi.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors mediating ligand-dependent transactivation. Among the 3 isoforms, PPAR- alpha is involved in lipid metabolism in the liver, while PPAR-gamma(-gamma1 and -gamma2) is involved in adipocyte differentiation. Recently, PPARs have been suggested to be involved in renal electrolyte metabolism as well as atherosclerosis. PPAR-alpha is known to regulate cytochrome P450 gene expression, and may possibly affect sodium retention in the kidney. Moreover, PPAR-gamma is involved in the transcription regulation of blood pressure regulatory genes, including thromboxane and angiotensin II type 1 receptors. In the kidney, although expression of PPARs has been reported, detailed immunohistochemical analyses have not been performed. We here generated isoform-specific anti-PPAR antibodies to localize their proteins in the kidney. Anti-PPAR antibodies were raised against synthetic peptides. Their isoform specificity was confirmed by immunoblot analyses, immunoprecipitations, and antibody supershift experiments by electrophoretic mobility shift assay. We therefore studied the protein expression of PPARs in the kidney of adult Sprague-Dawley rats using these antibodies. Immunoblot analyses demonstrated protein expression of PPAR-alpha and -gamma1, but not of -gamma2, in the kidney nuclear extracts. Immunohistochemical analyses demonstrated that both PPAR-alpha and -gamma1 proteins were widely expressed in the nuclei of mesangial and epithelial cells in glomeruli, proximal and distal tubules, the loop of Henle, medullary collecting ducts, and intima/media of renal vasculatures. PPAR-alpha and -gamma1 proteins are thus widely expressed along the nephron segments, and may affect gene expression at these segments. Further studies will be needed to identify additional target genes for PPARs along the nephron segments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15253107     DOI: 10.1291/hypres.27.417

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  12 in total

1.  Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

Authors:  Emily Borsting; Vicki Pei-Chun Cheng; Chris K Glass; Volker Vallon; Robyn Cunard
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-14

2.  Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis.

Authors:  Jorge E Toblli; Gabriel Cao; Jorge F Giani; Margarita Angerosa; Fernando P Dominici; Nestor F Gonzalez-Cadavid
Journal:  Kidney Blood Press Res       Date:  2010-11-11       Impact factor: 2.687

Review 3.  Recent advances in intravesical drug/gene delivery.

Authors:  Pradeep Tyagi; Pao-Chu Wu; Michael Chancellor; Naoki Yoshimura; Leaf Huang
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

4.  hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.

Authors:  Yingjian Li; Xiaoyan Wen; Bradley C Spataro; Kebin Hu; Chunsun Dai; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2005-11-16       Impact factor: 10.121

5.  Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors.

Authors:  Tengis S Pavlov; John D Imig; Alexander Staruschenko
Journal:  PPAR Res       Date:  2010-06-14       Impact factor: 4.964

6.  Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.

Authors:  Atsushi Tanaka; Tsukasa Nakamura; Eiichi Sato; Atsuko Chihara; Koichi Node
Journal:  CEN Case Rep       Date:  2020-01-16

Review 7.  PPARγ agonist beyond glucose lowering effect.

Authors:  Akira Sugawara; Akira Uruno; Masataka Kudo; Ken Matsuda; Chul Woo Yang; Sadayoshi Ito
Journal:  Korean J Intern Med       Date:  2011-03-02       Impact factor: 2.884

8.  The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.

Authors:  M C Thomas; K A Jandeleit-Dahm; C Tikellis
Journal:  PPAR Res       Date:  2012-02-12       Impact factor: 4.964

9.  Peroxisome proliferator-activated receptors in diabetic nephropathy.

Authors:  Shinji Kume; Takashi Uzu; Keiji Isshiki; Daisuke Koya
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

10.  PPARgamma in Kidney Physiology and Pathophysiology.

Authors:  Eva Kiss-Tóth; Tamás Roszer
Journal:  PPAR Res       Date:  2009-03-10       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.